SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 7, 2024
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-19125
|
33-0336973
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock, $.001 Par Value
|
|
“IONS”
|
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s
financial results for the quarter ended March 31, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the
Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding
non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of
the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press Release dated May 7, 2024.
|
| |
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
Ionis Pharmaceuticals, Inc.
|
| |
|
|
Dated: May 7, 2024
|
By:
|
/s/ Patrick R. O’Neil
|
| |
|
Patrick R. O’Neil
|
| |
|
Executive Vice President, Chief Legal
Officer and General Counsel
|
Exhibit 99.1
Ionis reports first quarter 2024 financial results
WAINUATM launch on track; EU and Canada approval decisions expected this year
Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission
Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions
On track to achieve 2024 financial guidance
CARLSBAD, Calif., May 7, 2024 – Ionis
Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the first quarter ended March 31, 2024.
“Ionis is off to a great start in 2024, as we continue to execute on our vision to bring better futures to people with serious diseases. The WAINUA launch for hereditary
ATTR polyneuropathy is progressing well with AstraZeneca. And we are one step closer to our first independent launch with our NDA submission for olezarsen, which is supported by robust data positioning olezarsen to make a profound difference for
people with FCS,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “We look forward to presenting positive Phase 3 donidalorsen data, along with data from our open-label extension and ‘switch’ studies in patients with HAE at EAACI later
this month, setting the stage for Ionis’ second independent launch. Additionally, we have multiple upcoming data readouts from our mid-stage programs that, if positive, could advance into Phase 3 development, further strengthening our ability to
deliver a steady cadence of potentially transformational medicines for years to come.”
First Quarter 2024 Summary Financial Results(1):
| |
|
Three months ended
March 31,
|
|
| |
|
2024
|
|
|
2023
|
|
| |
|
(amounts in millions)
|
|
|
Total revenue
|
|
$
|
119
|
|
|
$
|
131
|
|
|
Operating expenses
|
|
$
|
269
|
|
|
$
|
245
|
|
|
Operating expenses on a non-GAAP basis
|
|
$
|
238
|
|
|
$
|
218
|
|
|
Loss from operations
|
|
$
|
(150
|
)
|
|
$
|
(114
|
)
|
|
Loss from operations on a non-GAAP basis
|
|
$
|
(119
|
)
|
|
$
|
(87
|
)
|
|
(1) |
Reconciliation of GAAP to non-GAAP basis contained later in this release.
|
Financial Highlights
| • |
Revenue for the first quarter of 2024 earned from numerous diverse sources, including a new source of royalty revenue with the launch of WAINUA in the U.S.
|
| • |
Continued strategic investments to bring WAINUA, olezarsen and donidalorsen to patients drove increased operating expenses in the first quarter of 2024 compared to the same period last year
|
| • |
Cash and short-term investments of $2.2 billion as of March 31, 2024 enable continued investments to drive increasing value, including supporting our planned upcoming launches
|
| • |
Reaffirmed 2024 financial guidance
|
Recent Marketed Medicines Highlights
| • |
WAINUA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) generated sales of $5 million in the first partial quarter of launch resulting in
royalty revenue of $1 million for Ionis in the first quarter of 2024
|
| • |
SPINRAZA for the treatment of spinal muscular atrophy (SMA) generated global sales of $341 million resulting in royalty revenue of $38 million in the first quarter of 2024
|
|
o |
Biogen presented new positive neurofilament light chain (NfL) biomarker data from the Phase 4 RESPOND study of SMA patients adding further evidence supporting the potential benefit of SPINRAZA in
infants and toddlers who had unmet medical needs after treatment with gene therapy
|
Recent Late-Stage Pipeline Highlights
| • |
Eplontersen granted Fast Track designation by the FDA for the treatment of patients with ATTR cardiomyopathy
|
| • |
Olezarsen achieved multiple milestones advancing it closer to potentially addressing two distinct populations of patients with urgent unmet need, familial chylomicronemia syndrome (FCS) and severe
hypertriglyceridemia (sHTG):
|
|
o |
Submitted NDA to the FDA for FCS
|
|
o |
Presented positive Phase 3 Balance study data in patients with FCS with a simultaneous publication in the New England Journal of
Medicine
|
|
o |
Presented positive Phase 2b Bridge study data in patients with HTG and sHTG with a simultaneous publication in the New England
Journal of Medicine
|
|
o |
Opened Expanded Access Program (EAP) for FCS in the U.S.
|
|
o |
Granted Breakthrough Therapy and Orphan Drug designations by the FDA for the treatment of patients with FCS
|
|
o |
Completed enrollment of the Phase 3 CORE pivotal study and ESSENCE supportive exposure study for sHTG; CORE2 confirmatory pivotal study on track to fully enroll mid-year
|
| • |
Donidalorsen achieved multiple milestones advancing it closer to potentially becoming a first-in-class RNA-targeted prophylactic treatment for people with hereditary angioedema (HAE):
|
|
o |
Reported positive topline data from the Phase 3 OASIS-HAE study in patients treated every four weeks or every eight weeks; preparing to submit NDA
|
|
o |
Opened EAP for HAE in the U.S.
|
|
o |
Granted Orphan Drug designation by EMA
|
| • |
Bepirovirsen granted Fast Track designation by the FDA for the treatment of patients with chronic hepatitis B (CHB)
|
Recent Other Pipeline Highlights
| • |
Reported positive Phase 2 data for ION224 (DGAT2) in patients with metabolic dysfunction-associated steatohepatitis (MASH)
|
| • |
Initiated the Phase 1/2 Orbit study of ION356 (PLP1) in patients with Pelizaeus-Merzbacher disease (PMD)
|
First Quarter 2024 Financial Results
“Our first quarter results keep us on track to achieve our 2024 financial guidance. With the launch of WAINUA in the U.S. underway, we are excited to add WAINUA
royalties to our meaningful revenues in the first quarter. We believe WAINUA is uniquely positioned in this growing market to address the needs of ATTRv-PN patients who remain significantly underserved, especially as it is the only approved medicine
with monthly dosing that can be self-administered via an auto injector,” said Elizabeth L. Hougen, chief financial officer of Ionis. “We continued to invest our capital resources in our near-term commercial opportunities, wholly owned pipeline and
technology. We expect our modest expense growth this year to be driven by our activities to support the WAINUA launch and planned launches for olezarsen and donidalorsen with R&D expenses
approaching steady state as several late-stage studies have recently ended. We believe the investments we are making today and plan to make over the next few years position Ionis to drive increasing value for patients and stakeholders.”
Revenue
Ionis’ revenue was comprised of the following:
| |
|
Three months ended
|
|
| |
|
March 31,
|
|
| |
|
2024
|
|
|
2023
|
|
|
Revenue:
|
|
(amounts in millions)
|
|
|
Commercial revenue:
|
|
|
|
|
|
|
|
SPINRAZA royalties
|
|
$
|
38
|
|
|
$
|
50
|
|
|
WAINUA royalties
|
|
|
1
|
|
|
|
-
|
|
|
Other commercial revenue:
|
|
|
|
|
|
|
|
|
|
TEGSEDI and WAYLIVRA revenue, net
|
|
|
9
|
|
|
|
7
|
|
|
Licensing and other royalty revenue
|
|
|
11
|
|
|
|
11
|
|
|
Total commercial revenue
|
|
|
59
|
|
|
|
68
|
|
|
Research and development revenue:
|
|
|
|
|
|
|
|
|
|
Amortization from upfront payments
|
|
|
42
|
|
|
|
16
|
|
|
Milestone payments
|
|
|
7
|
|
|
|
23
|
|
|
Collaborative agreement revenue
|
|
|
49
|
|
|
|
39
|
|
|
WAINUA joint development revenue
|
|
|
11
|
|
|
|
24
|
|
|
Total research and development revenue
|
|
|
60
|
|
|
|
63
|
|
|
Total revenue
|
|
$
|
119
|
|
|
$
|
131
|
|
Commercial revenue in the first quarter of 2024 included a new source of royalty revenue with the launch of WAINUA in the U.S. during the first quarter of 2024. While
the number of patients on SPINRAZA treatment remained consistent globally, royalties decreased year over year primarily due to the timing of shipments in several markets outside the U.S. Ionis’ commercial revenue in the first quarter of 2024 also
included royalties from the net sales of QALSODY, which Biogen launched in the second quarter of 2023.
R&D revenue in the first quarter of 2024 included increased revenue from the amortization of upfront payments compared to the same period last year due to the new
collaborations Ionis entered into last year with Roche and Novartis. This increase was offset by decreases in milestone payments due to timing and WAINUA joint development revenue, which decreased as development activities relating to ATTRv-PN
wound down with the launch of WAINUA underway.
Operating Expenses
Ionis’ operating expenses increased in the first quarter of 2024 compared to the same period in 2023, consistent with expectations. SG&A expenses increased year
over year primarily due to the launch of WAINUA in the U.S. and launch preparation activities for olezarsen and donidalorsen. R&D expenses increased compared to the same period last year due to the timing of development activities and are
expected to stabilize in 2024 as several late-stage studies have ended.
Balance Sheet
As of March 31, 2024, Ionis’ cash, cash equivalents and short-term investments decreased to $2.2 billion compared to $2.3 billion at December 31, 2023. As the year
progresses, the Company plans to continue deploying its capital resources toward growth opportunities. Ionis’ working capital also decreased over the same period primarily due to the Company’s lower cash and short-term investments balance.
Webcast
Management will host a conference call and webcast to discuss Ionis’ first quarter 2024 results at
11:30 a.m. Eastern time on Tuesday, May 7, 2024. Interested parties may access the webcast here. A webcast replay
will be available for a limited time at the same address. To access the Company’s first quarter 2024 earnings slides click here.
For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/, respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY.
Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).
INDICATION for WAINUA™ (eplontersen)
WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
IMPORTANT SAFETY INFORMATION for WAINUA™ (eplontersen)
WARNINGS AND PRECAUTIONS
Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
ADVERSE REACTIONS
Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).
Please see link to U.S. Full Prescribing
Information for WAINUA.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading
pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about
Ionis, visit Ionispharma.com and follow us on X
(Twitter) and LinkedIn.
Ionis’ Forward-looking Statement
This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial
medicines, additional medicines in development and technologies. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the
endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such
forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no
obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual
report on Form 10-K for the year ended December 31, 2023, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea
Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. QALSODYTM is a trademark of Biogen. SPINRAZA® is a
registered trademark of Biogen. WAINUATM is a registered trademark of the AstraZeneca group of companies.
Ionis Investor Contact:
D. Wade Walke, Ph.D.
info@ionisph.com 760-603-2331
Ionis Media Contact:
Hayley Soffer
CorporateCommunications@ionisph.com 760-603-4679
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Millions, Except Per Share Data)
|
|
Three months ended
March 31,
|
|
| |
|
2024
|
|
|
2023
|
|
| |
|
(unaudited)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
Commercial revenue:
|
|
|
|
|
|
|
|
SPINRAZA royalties
|
|
$
|
38
|
|
|
$
|
50
|
|
|
WAINUA royalties
|
|
|
1
|
|
|
|
-
|
|
|
Other commercial revenue
|
|
|
20
|
|
|
|
18
|
|
|
Total commercial revenue
|
|
|
59
|
|
|
|
68
|
|
|
Research and development revenue:
|
|
|
|
|
|
|
|
|
|
Collaborative agreement revenue
|
|
|
49
|
|
|
|
39
|
|
|
WAINUA joint development revenue
|
|
|
11
|
|
|
|
24
|
|
|
Total research and development revenue
|
|
|
60
|
|
|
|
63
|
|
|
Total revenue
|
|
|
119
|
|
|
|
131
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
2
|
|
|
|
1
|
|
|
Research, development and patent
|
|
|
214
|
|
|
|
198
|
|
|
Selling, general and administrative
|
|
|
53
|
|
|
|
46
|
|
|
Total operating expenses
|
|
|
269
|
|
|
|
245
|
|
|
Loss from operations
|
|
|
(150
|
)
|
|
|
(114
|
)
|
| |
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
Interest expense related to the sale of future royalties
|
|
|
(18
|
)
|
|
|
(16
|
)
|
|
Other income, net
|
|
|
25
|
|
|
|
17
|
|
|
Loss before income tax expense
|
|
|
(143
|
)
|
|
|
(113
|
)
|
| |
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
-
|
|
|
|
(11
|
)
|
| |
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(143
|
)
|
|
$
|
(124
|
)
|
| |
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.98
|
)
|
|
$
|
(0.87
|
)
|
|
Shares used in computing basic and diluted net loss per share
|
|
|
146
|
|
|
|
143
|
|
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss
(In Millions)
| |
|
Three months ended
March 31,
|
|
| |
|
2024
|
|
|
2023
|
|
| |
|
(unaudited)
|
|
|
As reported research, development and patent expenses according to GAAP
|
|
$
|
214
|
|
|
$
|
198
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(22
|
)
|
|
|
(20
|
)
|
|
Non-GAAP research, development and patent expenses
|
|
$
|
192
|
|
|
$
|
178
|
|
| |
|
|
|
|
|
|
|
|
|
As reported selling, general and administrative expenses according to GAAP
|
|
$
|
53
|
|
|
$
|
46
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(9
|
)
|
|
|
(7
|
)
|
|
Non-GAAP selling, general and administrative expenses
|
|
$
|
44
|
|
|
$
|
39
|
|
| |
|
|
|
|
|
|
|
|
|
As reported operating expenses according to GAAP
|
|
$
|
269
|
|
|
$
|
245
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
Non-GAAP operating expenses
|
|
$
|
238
|
|
|
$
|
218
|
|
| |
|
|
|
|
|
|
|
|
|
As reported loss from operations according to GAAP
|
|
$
|
(150
|
)
|
|
$
|
(114
|
)
|
|
Excluding compensation expense related to equity awards
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
Non-GAAP loss from operations
|
|
$
|
(119
|
)
|
|
$
|
(87
|
)
|
| |
|
|
|
|
|
|
|
|
|
As reported net loss according to GAAP
|
|
$
|
(143
|
)
|
|
$
|
(124
|
)
|
|
Excluding compensation expense related to equity awards and related tax effects
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
Non-GAAP net loss
|
|
$
|
(112
|
)
|
|
$
|
(97
|
)
|
Reconciliation of GAAP to Non-GAAP Basis
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were
adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for
financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further,
the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.
IONIS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(In Millions)
| |
|
March 31,
2024
|
|
|
December 31,
2023
|
|
| |
|
(unaudited)
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
Cash, cash equivalents and short-term investments
|
|
$
|
2,206
|
|
|
$
|
2,331
|
|
|
Contracts receivable
|
|
|
5
|
|
|
|
98
|
|
|
Other current assets
|
|
|
204
|
|
|
|
213
|
|
|
Property, plant and equipment, net
|
|
|
73
|
|
|
|
71
|
|
|
Right-of-use assets
|
|
|
169
|
|
|
|
172
|
|
|
Other assets
|
|
|
107
|
|
|
|
105
|
|
|
Total assets
|
|
$
|
2,764
|
|
|
$
|
2,990
|
|
| |
|
|
|
|
|
|
|
|
|
Liabilities and stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
Current portion of deferred contract revenue
|
|
$
|
130
|
|
|
$
|
151
|
|
|
0.125% convertible senior notes, net – short-term
|
|
|
44
|
|
|
|
44
|
|
|
Other current liabilities
|
|
|
153
|
|
|
|
253
|
|
|
1.75% convertible senior notes, net
|
|
|
563
|
|
|
|
562
|
|
|
0% convertible senior notes, net
|
|
|
626
|
|
|
|
625
|
|
|
Liability related to sale of future royalties, net
|
|
|
525
|
|
|
|
514
|
|
|
Long-term lease liabilities
|
|
|
169
|
|
|
|
171
|
|
|
Long-term obligations, less current portion
|
|
|
42
|
|
|
|
42
|
|
|
Long-term deferred contract revenue
|
|
|
215
|
|
|
|
241
|
|
|
Total stockholders’ equity
|
|
|
297
|
|
|
|
387
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
2,764
|
|
|
$
|
2,990
|
|
Key 2024 Value Driving Events(1)
|
New Product Launches
|
|
Program
|
Indication
|
Achieved
|
|
WAINUA
|
ATTRv-PN
|
|
|
Olezarsen
|
FCS
|
|
|
QALSODY (EU)
|
SOD1-ALS
|
|
|
Regulatory Actions
|
|
Program
|
Indication
|
Regulatory Action
|
Achieved
|
|
Eplontersen
|
ATTRv-PN
|
Additional OUS filings
|
|
|
EMA approval decision
|
|
|
Additional OUS approval decision(s)
|
|
|
Olezarsen
|
FCS
|
NDA filing
|
|
|
FDA approval decision
|
|
|
EU filing
|
|
|
Canada filing
|
|
|
Donidalorsen
|
HAE
|
NDA filing
|
|
|
QALSODY
|
SOD1-ALS
|
EMA approval decision
|
|
|
Key Phase 3 Clinical Data Events
|
|
Program
|
Indication
|
Event
|
Achieved
|
|
Olezarsen
|
FCS
|
Balance study full data
|
|
|
Donidalorsen
|
HAE
|
OASIS-HAE topline data
|
|
|
Donidalorsen
|
HAE
|
OASIS-HAE full data
|
|
|
Donidalorsen
|
HAE
|
OASIS-Plus: OLE + Switch data
|
|
|
Key Phase 2 Clinical Data Events
|
|
Program
|
Indication
|
Event
|
Achieved
|
|
Donidalorsen
|
HAE
|
3-year Phase 2 OLE data
|
|
|
IONIS-FB-LRx
|
IgAN
|
Phase 2 data
|
|
|
IONIS-FB-LRx
|
GA
|
GOLDEN study data
|
|
|
ION224 (DGAT2)
|
NASH
|
Phase 2 data
|
|
|
ION582 (UBE3A)
|
Angelman syndrome
|
HALOS study data
|
|
|
ION541 (ATXN2)
|
ALS
|
ALSpire study data
|
|
| |
(1) |
Timing expectations based on current assumptions and subject to change.
|
# # #
9